Mirion Technologies, Inc. (MIR) | The Buildout — AI Infrastructure

The Verdict

Mirion sells the instruments, qualified spare parts and software that let nuclear plants and cancer-treatment centers use radiation safely. Inside a reactor, its detectors and controls sit on the operating fleet and on new reactors, and its reverse-engineered components keep aging plants running. In medicine, it supplies radiation-therapy quality-assurance hardware and dosimetry. For the AI buildout the link is indirect: data centers are pulling on electricity supply, which has renewed interest in nuclear and small modular reactors. Mirion's exposure runs through nuclear demand, not through AI products directly.

Earnings

Mirion reported Q2 2026 revenue of $266.8M, up 20% year over year, though organic growth was just 1%. Adjusted EBITDA rose 27.5% to $65.3M and margins expanded 150 basis points — over 200 excluding M&A and a one-time tariff refund. Total orders were $291M, up 40% including $62M from Paragon and Certrec, and backlog stood above $1.1B, up about 40%. Adjusted free cash flow was $49M in the quarter and $60M in the first half, the best first half since going public.

Management tone: Management was more candid about timing and execution than in prior quarters. The CFO owned a missed order-cadence guide — you may recall sequential order growth of 15%–20% came in at 14% net of China — and disclosed an unexpected ~$18M Chinese new-build cancellation, calling the target an audacious one while holding it. On Medical, tone shifted from prior optimism, with nuclear medicine and dosimetry guidance cut. On margins, Q1 contraction gave way to Q2 expansion in both segments, but the next quarter's Nuclear & Safety margin is guided to contract.

Management Guidance

Management maintained that full-year 2026 guidance is unchanged from April, with the full-year adjusted EBITDA margin midpoint around 25.5%. On the Q2 call management initiated a third-quarter guide of high-single-digit consolidated organic growth, with Nuclear & Safety mid-single digits and Medical high single digits, and said consolidated margins should expand while Nuclear & Safety margins contract. For the second half, organic growth is guided to 7.5%–11.2% and adjusted EBITDA margin to roughly 27%–29%; management said about 81% of expected full-year revenue is covered by first-half actuals plus backlog conversion.

Trajectory

Reported revenue has grown in the high teens and twenties, but most of that came from acquisitions — Paragon and Certrec — with organic growth of about 3% in Q1 2026 and 1% in Q2 2026. Margins follow a similar split: first-half 2026 adjusted EBITDA margin was 22.8%, down 23 basis points year over year on dilutive M&A and mix, and the second half is guided to roughly 27%–29% on operating leverage. Reported figures show gross margin expanding about 310 basis points and EBITDA margin up about 240 basis points on a trailing basis, with free cash flow converting well above net income. The question the numbers pose is whether the guided second-half organic step-up turns the order book into revenue.

The Model

The model projects FY+1 revenue of $1,140M and EBITDA of $254M, a 22.3% margin. For FY+2 it projects revenue of $1,245M and EBITDA of $311M, a 25.0% margin. The near-term case rests on backlog conversion and the guided second-half organic ramp; the FY+2 margin sits between management's FY2026 guide and its 30% 2028 target, implying the operating-leverage and procurement bridge has to keep working.

Projections are the median of 5 independent model runs. The model’s revenue sits 4.1% above analyst consensus.

Management maintained that full-year 2026 guidance is unchanged from April, with the full-year adjusted EBITDA margin midpoint around 25.5%. On the Q2 call management initiated a third-quarter guide of high-single-digit consolidated organic growth, with Nuclear & Safety mid-single digits and Medical high single digits, and said consolidated margins should expand while Nuclear & Safety margins contract. For the second half, organic growth is guided to 7.5%–11.2% and adjusted EBITDA margin to roughly 27%–29%; management said about 81% of expected full-year revenue is covered by first-half actuals plus backlog conversion.

What Could Go Right — and Wrong

Looking Ahead

Over the next year the story turns on whether the order book converts. Management guides a second-half 2026 organic step-up and a 27%–29% adjusted EBITDA margin. It also points to SMR revenue above 3% of total by year-end 2026, a roughly $280M pipeline of large opportunities, and a Perma-Fix partnership for DOE and federal nuclear cleanup announced in August 2026. The 2028 30% margin target and the ~2.5x leverage path if no M&A are the longer markers.

Financials

Annual Summary

Key Ratios (Trailing)

The Company

Mirion describes itself as delivering 'vital protection that unlocks the transformative potential of radiation to move science, industry and medicine forward.' It supplies products, services and software that let customers use ionizing radiation safely. Its Nuclear & Safety segment makes radiation monitoring systems, reactor instrumentation and control detectors, imaging systems, waste-management systems, lab analysis equipment and military CBRNE gear. Its Medical segment makes radiation-therapy quality-assurance hardware and software, dose calibrators and dosimetry products. Customers are nuclear power operators, hospitals and labs.

Mirion produces in eight countries: the United States, Canada, France, Germany, Belgium, Estonia, Finland and the United Kingdom. It has been optimizing its factory footprint rather than expanding, and says it generally has more capacity than it needs. It has also consolidated some nuclear-medicine factories, with lead times coming down. Recent acquisitions, Paragon Energy Solutions and Certrec, added a commercial-grade parts and regulatory-software layer on top of the hardware.

Business Segments

Competitive Landscape

Mirion competes in fragmented markets. Its 10-K lists Nuclear & Safety competitors including Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Fluke (Fortive) and Framatome, and Medical competitors including Landauer (Fortive), PTW, IBA, Standard Imaging and LAP. Management frames its installed-base breadth as a differentiator; the source frames that as a breadth claim rather than a stated moat, since the competitor set is fragmented.

Supply Chain

Mirion sits several layers below the reactors it serves: it sells instruments, qualified spares and software to nuclear operators, to OEM channels like EDF/Framatome and Westinghouse, and to hospitals. Neighbors NuScale, Duke and NextEra confirm parts of the relationship.